Nicolas Q Wolnick, Marissa R Dickson, Thaddaeus A Webster, Roger P Connolly, Nancy Fernandes, Vesela Encheva, Hunter Crittenden, Jessica Hodgkins, Brian C Hadley, Gabriella Palermo, Shannon J Hendrick, Roy A Newell, Genevieve Gray, Christian Siltanen, Julia Armstrong, Brandon J Downey, Carrie Mason
While monospecific antibodies have long been the foundational offering of protein therapeutics, recent advancements in antibody engineering have allowed for the development of far more complex antibody structures. Novel molecular format (NMF) proteins, such as bispecific antibodies (BsAbs), are structures capable of multispecific binding, allowing for expanded therapeutic functionality. As demand for NMF proteins continues to rise, biomanufacturers face the challenge of increasing bioreactor process productivity while simultaneously maintaining consistent product quality...
April 23, 2024: Bioprocess and Biosystems Engineering